CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

Jiang, Shuang; Wang, Xiaobo; Zhang, Zhiran; Sun, Li; Pu, Yunzhu; Yao, Hong-Juan; Li, Jingcao; Liu, Yan; Zhang, Yingge; Zhang, Weijing

doi:10.2147/ijn.s115428

Cited by 39 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, limitations such as irreversible rapid degradation, short blood half-life as well as lack of targeting capacity strictly require the aid of additional DDSs for its further application in cancer therapy (Ding et al., 2017). Recently, monoclonal antibodies that can target corresponding receptors on the surface of cancer cells to exert specific functions are widely recognized as promising candidates for chemotherapy of cancer (Shuang et al., 2016; Colzani et al., 2018). Cetuximab (Cet) is a commonly adopted monoclonal antibody that targets epidermal growth factor receptor (EGFR) to inhibits the EGF signaling in cancer cells (Wang et al., 2017).…”

Section: Introductionmentioning

confidence: 99%

Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer

Zhang

Wei

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

Combinational therapy is usually considered as a preferable approach for effective cancer therapy. Especially, combinational chemo and photothermal therapy is of particular interest due to its high flexibility as well as efficiency. In this article, we the silica nanoparticles (SLN) were surface conjugated with Cetuximab (Cet-SLN) to target epidermal growth factor receptor (EGFR), a common receptor that usually observed to overexpress in multiple breast cancers. Moreover, the high drug loading capacity of Cet-SLN was employed to encapsulate photothermal agent indocyanine green (ICG) to finally fabricate a versatile drug delivery system (DDS) able to co-deliver Cet and ICG (Cet-SLN/ICG) for combinational chemo-photothermal therapy of breast cancer. The obtained results clearly demonstrated that Cet-SLN/ICG was well-dispersed nanoparticles with preferable stability under physiological condition. Furthermore, due to the conjugation of Cet, Cet-SLN/ICG could target EGFR which overexpress in MCF-7 cells. Most importantly, both in vitro and in vivo results suggested that compared with Cet or ICG alone, the Cet-SLN/ICG showed superior anticancer efficacy. In conclusion, Cet-SLN/ICG could be a potential platform for effective combinational chemo-photothermal therapy for breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer

Zhang

Wei

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

show abstract

“… 28 Recently, various researchers have demonstrated the selective internalization of monoclonal antibody-modified nanoparticles in comparison to non-modified nanoparticles. 29 , 30 …”

Section: Discussionmentioning

confidence: 99%

<p>Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy</p>

Dorjsuren¹,

Chaurasiya²,

Ye³

et al. 2020

IJN

View full text Add to dashboard Cite

Background One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency. Methods To exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model. Results The resulting CET-DOX-CMNP–TSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7°C and 48.7°C, respectively, compared with saline-treated mice body temperature ie, 35.2°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery. Conclusion Our studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer.

show abstract

“…from nanoparticles was only 20%. 45 Similarly, about 28% and 24% of gemcitabine burst were released during the first 24 hours from AS1411 aptamer-conjugated PEG-PLGA nanoparticles and non-targeted nanoparticles, respectively. After burst release, up to 44% and 41% sustained release were observed in both formulations at 120 hours and pH 5.5 for targeted and non-targeted nanoparticles, respectively.…”

Section: Controlled Drug Release Of Active Targeting Nanoparticlesmentioning

confidence: 95%

“…It exhibited higher cytotoxic activity against CD20positive human Burkitt's lymphoma cells (Raji) compared with non-targeted nanoparticles. 45 The anti-CD47 monoclonal antibody-conjugated iron oxide magnetic nanoparticle delivering gemcitabine to the target CD47 receptor was shown to increase drug cellular uptake by human pancreatic ductal adenocarcinoma cells (Panc215 and Panc354). Their cytotoxic activity was also significantly enhanced.…”

Section: Antibodies or Antibody Fragmentsmentioning

confidence: 99%

Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review

Muhamad

Plengsuriyakarn²,

Na‐Bangchang³

2018

IJN

319

153

View full text Add to dashboard Cite

Patients treated with conventional cancer chemotherapy suffer from side effects of the drugs due to non-selective action of chemotherapeutic drugs to normal cells. Active targeting nanoparticles that are conjugated to targeting ligands on the surface of nanoparticles play an important role in improving drug selectivity to the cancer cell. Several chemotherapeutic drugs and traditional/herbal medicines reported for anticancer activities have been investigated for their selective delivery to cancer cells by active targeting nanoparticles. This systematic review summarizes reports on this application. Literature search was conducted through PubMed database search up to March 2017 using the terms nanoparticle, chemotherapy, traditional medicine, herbal medicine, natural medicine, natural compound, cancer treatment, and active targeting. Out of 695 published articles, 61 articles were included in the analysis based on the predefined inclusion and exclusion criteria. The targeting ligands included proteins/peptides, hyaluronic acid, folic acid, antibodies/antibody fragments, aptamer, and carbohydrates/polysaccharides. In vitro and in vivo studies suggest that active targeting nanoparticles increase selectivity in cellular uptake and/or cytotoxicity over the conventional chemotherapeutic drugs and non-targeted nanoparticle platform, particularly enhancement of drug efficacy and safety. However, clinical studies are required to confirm these findings.

show abstract

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

Cited by 39 publications

References 27 publications

Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer

Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer

<p>Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy</p>

Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review

Contact Info

Product

Resources

About